Literature DB >> 2323591

Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients.

P A Testoni1, F Bagnolo, L Fanti, S Passaretti, A Tittobello.   

Abstract

We have evaluated the effect of cisapride on interdigestive antroduodenal motility during a prolonged oral therapy in 20 consecutive dyspeptic subjects. Individuals with less than two migrating motor complexes (MMCs) starting from the antral region in 240 minutes and without evidence of upper gastrointestinal tract diseases were randomly treated with either cisapride (10 cases), or placebo (10 cases) for 15 days. Computerised manometry of antroduodenal region was performed for 240 minutes, in basal conditions and on the 15th day of therapy. Symptomatic evaluation of patients was also performed before and after treatment. After cisapride administration, a significant increase in the incidence of antral migrating motor complexes was noticed (p = 0.022); likewise, the motility index, calculated for phase-2 periods, appeared to be significantly higher both in the antrum and in the duodenum (p less than 0.001). Symptomatic improvement was observed in both groups, with a hardly significant (p = 0.049) reduction of dyspeptic symptoms severity only but not of frequency in cisapride treated patients v controls. We conclude that longterm oral therapy with cisapride improves interdigestive antroduodenal motor activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323591      PMCID: PMC1378268          DOI: 10.1136/gut.31.3.286

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Abnormalities of the migrating motor complex in diabetics with autonomic neuropathy and diarrhea.

Authors:  C P Dooley; H M el Newihi; A Zeidler; J E Valenzuela
Journal:  Scand J Gastroenterol       Date:  1988-03       Impact factor: 2.423

2.  The unstimulated duodenal pressure activity in health humans.

Authors:  S Larsen; M Osnes
Journal:  Scand J Gastroenterol Suppl       Date:  1987

3.  Interdigestive motility pattern in subjects with duodenogastric bile reflux.

Authors:  P A Testoni; L Fanti; S Passaretti; E Masci; M Guslandi; A Tittobello
Journal:  Scand J Gastroenterol       Date:  1987-08       Impact factor: 2.423

4.  Abnormalities of interdigestive motility complex and increased duodenogastric reflux in gastric ulcer patients.

Authors:  M Miranda; C Defilippi; J E Valenzuela
Journal:  Dig Dis Sci       Date:  1985-01       Impact factor: 3.199

5.  Intestinal motility disorders.

Authors:  G R Vantrappen; J Janssens
Journal:  Dig Dis Sci       Date:  1984-05       Impact factor: 3.199

Review 6.  Motor disorders of the stomach.

Authors:  E Rock; L Malmud; R S Fisher
Journal:  Med Clin North Am       Date:  1981-11       Impact factor: 5.456

7.  Backwards and forwards with the migrating complex.

Authors:  D L Wingate
Journal:  Dig Dis Sci       Date:  1981-07       Impact factor: 3.199

8.  Duodenogastric reflux in humans: its relationship to fasting antroduodenal motility and gastric, pancreatic, and biliary secretion.

Authors:  F B Keane; E P Dimagno; J R Malagelada
Journal:  Gastroenterology       Date:  1981-10       Impact factor: 22.682

9.  The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine.

Authors:  G Vantrappen; J Janssens; J Hellemans; Y Ghoos
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

10.  Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormone patterns.

Authors:  W D Rees; J R Malagelada; L J Miller; V L Go
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

View more
  11 in total

Review 1.  Mechanisms of cisapride affecting gallbladder motility.

Authors:  R von Kiedrowski; S Huijghebaert; R Raedsch
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

2.  Patient-based assessment in dyspepsia: development and validation of Dyspepsia Symptom Severity Index (DSSI).

Authors:  N K Leidy; C Farup; A M Rentz; D Ganoczy; K L Koch
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

3.  The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis.

Authors:  R Corinaldesi; V Stanghellini; C Tosetti; E Rea; C Corbelli; M Marengo; N Monetti; L Barbara
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Role and integration of mechanisms controlling gastric emptying.

Authors:  M Horowitz; J Dent; R Fraser; W Sun; G Hebbard
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

Review 5.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Assessment by prolonged ambulatory manometry of the effect of oral cisapride on proximal small bowel inter-digestive motility.

Authors:  M J Benson; F D Castillo; J J Deeks; D L Wingate
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

7.  Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. A double-blind placebo-controlled clinical trial with cisapride.

Authors:  L Marzio; F DiFelice; M G Laico; B Imbimbo; D Lapenna; F Cuccurullo
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

8.  Influence of cisapride on gastric emptying of solids and liquids monitored by 13C breath tests.

Authors:  L P Duan; B Braden; W F Caspary; B Lembcke
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

Review 9.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

10.  Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia?

Authors:  F Mearin; X de Ribot; A Balboa; A Salas; M J Varas; M Cucala; R Bartolomé; J R Armengol; J R Malagelada
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.